L50 inhibition of Tat-dependent transactivation in cell-free, reconstituted transcription system and in transfected cells. by Matthew S. Lalonde (220537)

“…<p>DNA templates carrying the HIV promoter were transcribed in the presence or absence of recombinant Tat protein (+Tat) and increasing concentrations of the Tat peptidomimenic (L-50, left panel; L-51, right panel) (<b>A</b>); ρ identifies full-length transcripts and τ identifies transcripts ending at the terminator sequence inserted proximal to the promoter. …”

Higher frequency (50 Hz) conduction is associated with shortening of stationary, and an increase in distance between stationary mitochondria. by Marija Sajic (332611)

“…(D) The number of mitochondria separated by 1.5 µm (measured between their mid-points) decreased in axons conducting at 50 Hz (<i>n</i> = 15 axons, <i>n</i> = 288 mitochondria), and was significantly lower for mitochondria separated by 3 µm (<i>p</i><0.001), than in sham-stimulated group (<i>n</i> = 13 axons, <i>n</i> = 309 mitochondria; three animals per group), i.e., mitochondria were less clustered in stimulated axons. …”

DataSheet1_Expression and regulation of 42Sp50 in spotted scat (Scatophagus argus).docx by Fei Zhi (13191303)

“…<p>42Sp50 is an isoform of the eukaryotic translation elongation factor 1 A (eEF1A) and is vital for fish ovarian development. …”

The <i>Becn1</i> F121A mutation inhibits the BECN1-BCL2 interaction in vivo. by Altea Rocchi (3278457)

Age-adjusted Hazard Ratios (HR) for a hip fracture, lowest quartile of BMD compared to the higher three quartiles of BMD, measured with DXL of the calcaneus or DXA of the femoral n... by Hans Lundin (800973)

RNA Polymerase II CTD phosphatase Rtr1 fine-tunes transcription termination by Jose F. Victorino (8595885)

“…Globally, <i>rtr1Δ</i> leads to decreases in numerous noncoding RNAs that are linked to the Nrd1, Nab3 and Sen1 (NNS) -dependent RNAPII termination pathway. …”

Effects of the use of support electrolytes in electrochemical tests of Al-4wt.% Mg alloy exposed to bioethanol fuel by Estefanía Gauto (5555207)

50 µM resveratrol is toxic to C₂C₁₂ myotubes. by Kazuhiko Higashida (351645)

“…<p>(A) Exposure to 50 µM resveratrol (RSV) for 24 h is toxic to C₂C₁₂ myotubes resulting in a decrease in viable cells and (B) a decrease in ATP content. …”

Svaldi et al.’s “High Load” and “Low Load” groups from a soccer season (High Load percentiles: 25th = 4515 g, 50th = 5615 g, 75th = 12313 g; Low Load percentiles: 25th = 2425 g, 50... by Joshua Auger (9530081)

“…<p>Post-season adjustments to the High Load group: 19.7% reduction from decreasing inflation pressure from 1.10 bar (16 psi) to 0.55 bar (8 psi), 7.1% reduction from downsizing a size 5, 0.55 bar (8 psi) ball to size 4.5, 0.55 bar (8 psi) ball (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0240162#pone.0240162.t003" target="_blank">Table 3</a>), and a 20% reduction in number of hits based on average PLA per hit (Adjusted High Load percentiles: 25th = 2463 g, 50th = 3063 g, 75th = 6718 g).…”

PSD95 immunoreactivity. by Carola I. F. Janssen (414818)

“…No significant genotype nor diet effects were found (<i>p</i>>0.05). In the SEN, ApoE^-/- mice showed a slight trend (<i>p</i> = 0.064) for decreased PSD95 expression. …”

Effect of BNN27 treatment on stride length and width in male and female mice. by Kelly E. Glajch (3204465)

“…<p>Male Tg vehicle-treated mice exhibited a decrease in stride length (a, left) at p115 (p = 0.0136, Mann-Whitney <i>U</i> test) and stride width (b, left) at p95 (p = 0.0202, Mann-Whitney <i>U</i> test) relative to Wt vehicle-treated mice. …”

CD68 immunoreactivity. by Carola I. F. Janssen (414818)

“…<p>In the CA1, we observed a genotype × diet interaction (p = 0.001), there was a trend for increased inflammation in WT after HF supplementation (p = 0.052). …”

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

FOXO1 DNA Binding Domain Is Required to Suppress Activin-Induced <i>Fshb</i> Gene Expression. by Chung Hyun Park (665717)

The role of TLR9 on <i>Leishmania amazonensis</i> infection and its influence on intranasal LaAg vaccine efficacy by Juliana Elena Silveira Pratti (6397262)

“…<div><p><i>Leishmania (L</i>.<i>) amazonensis</i> is one of the etiological agents of cutaneous leishmaniasis (CL) in Brazil. …”

CDK2/Speedy A localization in <i>Cdk2</i>^<i>T160A</i> spermatocytes. by Nathan Palmer (264897)

“…Data are presented as individual foci counts for WT (orange bars, N = 72) and <i>Cdk2</i>^<i>T160A</i> (blue bars, N = 50); error bars are indicative of the mean and SD. …”

Neutrophils and inflammatory macrophages infiltration of the gut after IR was equally strong in WT and αβ T cell deficient mice. by Yi Yu (28902)

“…Representative density plots of live CD45⁺CD11b⁺ leukocytes in IEL are displayed in (A), and LPL in (B) showing an increase of Ly6G⁺ neutrophils and a reciprocal relative decrease of F4/80⁺ macrophages. C) Percentage of CD11b⁺ myeloid cells in WT and Tcra^tm1/mom following IR or ctrl treatment. …”

Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase by Safiatou T. Coulibaly (816058)

“…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”